Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.70
-0.57 (-2.26%)
At close: Mar 26, 2026, 4:00 PM EDT
24.70
0.00 (0.00%)
After-hours: Mar 26, 2026, 5:30 PM EDT
Castle Biosciences Revenue
In the year 2025, Castle Biosciences had annual revenue of $344.23M with 3.66% growth. Castle Biosciences had revenue of $87.01M in the quarter ending December 31, 2025, with 0.81% growth.
Revenue (ttm)
$344.23M
Revenue Growth
+3.66%
P/S Ratio
2.13
Revenue / Employee
$389,840
Employees
883
Market Cap
734.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 344.23M | 12.16M | 3.66% |
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
| Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
| Dec 31, 2017 | 13.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| CareDx | 379.81M |
| Fulgent Genetics | 322.67M |
| GRAIL | 147.17M |
CSTL News
- 3 days ago - Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript - Seeking Alpha
- 13 days ago - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB - GlobeNewsWire
- 17 days ago - DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - GlobeNewsWire
- 22 days ago - Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - GlobeNewsWire
- 23 days ago - Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - GlobeNewsWire
- 4 weeks ago - Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - GlobeNewsWire
- 5 weeks ago - Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire